Skip to content

Dyadic International Inc

DYAI· NasdaqCore metricsCIK 1213809

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -3.95%
Market cap
$14.63M
40.09M shares
Filings
542
$449.10K
Q3 2026−11.6% FY25 yoy
-$1.36M
Q3 2026N/M FY25 yoy
-$1.81M
Q3 2026N/M FY25 yoy
—
—
—
-$0.04
Q3 2026N/M FY25 yoy
$3.93M
Q3 2026−29.0% FY25 yoy
$14.63M
—
4.7×
—
—
—

Twelve months to Sep 30, 2026 · derived

Price

$0.36562.27%$0.6025past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$3.09MFY 2025
$3.50M0FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$3,090,345reported
FY 20242024-12-31$3,495,389reported
FY 20232023-12-31$2,898,806reported
FY 20222022-12-31$2,930,303reported
FY 20212021-12-31$2,403,831reported
FY 20202020-12-31$1,601,921reported
FY 20192019-12-31$1,681,076reported
FY 20182018-12-31$1,295,451reported
FY 20172017-12-31$758,420reported

Capital returns

Dividends and buybacks · FY2017 to FY2019
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2019—$0.00$0.00—27.36M sh+2.4%—
FY2018—$2.30M$2.30M—26.71M sh−5.7%—
FY2017—$6.22M$6.22M—28.33M sh——

Segments

Products
Revenue by Products, FY2021 to FY2025FY2021Research and Development · FY2021 · $2.40MFY2022License · FY2022 · $247.06KResearch and Development · FY2022 · $2.68MFY2023License · FY2023 · $352.94KResearch and Development · FY2023 · $2.55MFY2024Research and Development · FY2024 · $1.61MLicense · FY2024 · $1.89MResearch and Development · FY2024 · $1.61MFY2025Grant · FY2025 · $1.86MResearch and Development · FY2025 · $967.31KLicense · FY2025 · $265.00K
LineFY2025ShareChange
Grant$1.86M60%—
Research and Development$967.31K31%−39.7%
License$265.00K8.6%−86.0%
Research and Development———
Total$3.09M

From the 10-K filed Mar 25, 2026DYAI

Biological products, except diagnostic substances

Dyadic International Inc is the 73rd largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Dyadic International Inc · CIK 1213809 · Engraved from SEC EDGAR